Sign Up Today and Learn More About Viome Stock
Invest in or calculate the value of your shares in Viome or other pre-IPO companies through EquityZen's platform.
Viome Stock (VIOM)
Discovering predictive biomarkers to eradicate all diseases.
About Viome Stock
Founded
2016
Headquarters
Cupertino, CA, US
Total Funding
15.0M
Industries
Health Care, Food and Beverage
Viome is a team of leading entrepreneurs, scientists, and physicians. Their proven expertise is why Viome is the only private company trusted with exclusive license to technology first developed at the prestigious Los Alamos National Laboratory. Viome’s pioneering artificial learning engines are designed to not only analyze your data, but to aggregate all the biological data they receive. As the sample size grows, their machines will spot trends and influences, which will unlock scientific breakthroughs.
Viome Press Mentions
Stay in the know about the latest news on Viome
Weekly Recap: 14 Tech Press Releases You Need to See
prnewswire • Apr 18, 2025
Viome Launches AI-Powered Full Body Intelligence™ Test To Help You Stay Healthy, Slow Aging, and Make Illness Optional
prnewswire • Apr 14, 2025
Viome Launches AI-Powered Full Body Intelligence™ Test To Help You Stay Healthy, Slow Aging, and Make Illness Optional
newswire • Apr 14, 2025
Gut Microbiota Market Set to Reach US$ 3,600.1 Million by 2032, Growing at a Robust CAGR of 22.50% from 2024 to 2032
einpresswire • Nov 24, 2024
Viome secures $25M, hires former Amazon, Groupon, Samsung executive
mobihealthnews • Sep 17, 2024
Viome Management
Leadership team at Viome
Founder & President
Deepak Savadatti
Founder & CEO
Naveen Jain
Join now and verify your accreditation status to gain access to:
- Viome Current Valuation
- Viome Stock Price
- Viome Management
- Available deals in Viome and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Viome Cap Table and Funding History by Share Class and Liquidity Preferences
- Viome Revenue and Financials
- Viome Highlights
- Viome Business Model
- Viome Risk Factors
- Viome Research Report from SACRA Research
Trading Viome Stock
How to invest in Viome stock?
Accredited investors can buy pre-IPO stock in companies like Viome through EquityZen funds. These investments are made available by existing Viome shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Viome stock?
Shareholders can sell their Viome stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
